TheraPsil, a B.C.-based non-profit, has launched its first-ever research collaboration as it continues to advocate for the legalization of psilocybin for medical purposes.
Story continues below
This advertisement has not loaded yet, but your article continues below.
In collaboration with researchers from McGill University and the Centre for Psychedelic Research at Imperial College London, the quantitative research study aims to understand the impact of psilocybin-assisted psychotherapy on Canadian patients who experience end-of-life distress.
Over the past year, TheraPsil has supported more than 30 patients and 19 healthcare professionals in five different provinces to obtain Section 56 exemptions to the Controlled Drugs and Substances Act (CDSA) so they can legally use and possess psilocybin.
Read full article on The Growth Op
